CM Management LLC Decreases Position in Cytosorbents Co. (NASDAQ:CTSO)

CM Management LLC decreased its stake in Cytosorbents Co. (NASDAQ:CTSO) by 12.5% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 700,000 shares of the medical research company’s stock after selling 100,000 shares during the quarter. CM Management LLC owned about 1.28% of Cytosorbents worth $637,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Raymond James Financial Inc. purchased a new position in Cytosorbents during the fourth quarter worth $99,000. Geode Capital Management LLC raised its position in Cytosorbents by 7.5% in the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after purchasing an additional 32,415 shares during the period. Sargent Investment Group LLC lifted its stake in Cytosorbents by 13.4% in the third quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company’s stock worth $2,439,000 after purchasing an additional 192,747 shares during the last quarter. Finally, Skylands Capital LLC boosted its position in shares of Cytosorbents by 1.0% during the fourth quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company’s stock valued at $2,531,000 after buying an additional 26,195 shares during the period. Institutional investors own 32.87% of the company’s stock.

Analyst Upgrades and Downgrades

CTSO has been the subject of a number of recent analyst reports. HC Wainwright restated a “neutral” rating and set a $1.00 price objective on shares of Cytosorbents in a report on Monday, November 11th. StockNews.com started coverage on shares of Cytosorbents in a research note on Sunday, March 2nd. They set a “hold” rating for the company. Finally, D. Boral Capital restated a “buy” rating and issued a $10.00 price target on shares of Cytosorbents in a report on Tuesday, February 25th. Two research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Cytosorbents has a consensus rating of “Moderate Buy” and an average price target of $4.67.

Cytosorbents Trading Down 3.8 %

Shares of NASDAQ CTSO opened at $1.01 on Friday. Cytosorbents Co. has a twelve month low of $0.70 and a twelve month high of $1.61. The firm has a market cap of $55.23 million, a PE ratio of -2.81 and a beta of 0.78. The business has a fifty day simple moving average of $1.05 and a two-hundred day simple moving average of $1.05. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06.

Cytosorbents Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.